- Home
- EARN vs CRVO Comparison
EARN vs CRVO Comparison
Compare EARN & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- CRVO
- Stock Information
- Founded
- EARN 2012
- CRVO 2001
- Country
- EARN United States
- CRVO United States
- Employees
- EARN N/A
- CRVO N/A
- Industry
- EARN Real Estate Investment Trusts
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- CRVO Health Care
- Exchange
- EARN Nasdaq
- CRVO Nasdaq
- Market Cap
- EARN 177.0M
- CRVO 160.4M
- IPO Year
- EARN 2013
- CRVO N/A
- Fundamental
- Price
- EARN $6.90
- CRVO $15.71
- Analyst Decision
- EARN Hold
- CRVO Strong Buy
- Analyst Count
- EARN 2
- CRVO 4
- Target Price
- EARN $6.00
- CRVO $58.25
- AVG Volume (30 Days)
- EARN 371.1K
- CRVO 74.2K
- Earning Date
- EARN 08-12-2024
- CRVO 08-09-2024
- Dividend Yield
- EARN 13.89%
- CRVO N/A
- EPS Growth
- EARN 102.38
- CRVO N/A
- EPS
- EARN 0.23
- CRVO N/A
- Revenue
- EARN $18,419,000.00
- CRVO $9,653,281.00
- Revenue This Year
- EARN N/A
- CRVO $47.04
- Revenue Next Year
- EARN $51.24
- CRVO N/A
- P/E Ratio
- EARN $29.78
- CRVO N/A
- Revenue Growth
- EARN N/A
- CRVO 585.67
- 52 Week Low
- EARN $5.09
- CRVO $4.28
- 52 Week High
- EARN $7.26
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- EARN 49.04
- CRVO 49.68
- Support Level
- EARN $6.76
- CRVO $14.00
- Resistance Level
- EARN $6.95
- CRVO $16.69
- Average True Range (ATR)
- EARN 0.09
- CRVO 1.78
- MACD
- EARN -0.00
- CRVO -0.14
- Stochastic Oscillator
- EARN 43.75
- CRVO 36.93
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.